Introduction: Estrogen and Progesterone receptor (ER and PR respectively) status are widely used to predict response to hormonal therapy in both the adjuvant and metastatic setting. However a proportion of patients who are ER and PR positive will not respond to hormonal therapy and some patients will also develop resistance to estrogen based therapies. The aim of this study is to identify the role of ERβ, its isoforms and other biological markers in female breast cancer. Methods: Tissue microarrays were created to evaluate the expression of ERβ and its isoforms as well other hormone receptors (Androgen receptor (AR), Progesterone receptor B (PRB), Estrogen a receptors at phosphorylated at serines 118 (ERαS 118) and 167 (ERαS 167) and their correlation with clinico-pathological variables, overall survival (OS) and disease free survival (DFS). Experiments to identify eo- localisation of ERβ and also the effect of estrogen on the phospho specific ERa expression were also carried out. Results : Most of the biological markers showed significant correlation with clinicopathological variables, OS and DFS on univariate analysis. However the nuclear expression of ERβ2 also showed significant correlation with OS on multivariate analysis. The same fmding was noted on multivariate analysis of DFS with AR and ERα S167expression Conclusion: ERβ, AR and ERα S167expression appear to have significant roles as prognostic indicators in breast cancer.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:588752 |
| Date | January 2010 |
| Creators | Peter, Mark Bernard |
| Publisher | University of Leeds |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0175 seconds